MRNA is trading at $50.86 (-4.52%) amid broader market weakness fueled by hotter-than-expected PPI data and rising oil prices.
- The stock is tracking declines in the S&P 500 (-0.19%) and Dow (-0.43%) as geopolitical tensions in the Middle East weigh on investor sentiment.
- No company-specific catalysts explain the drop, with the next earnings report not scheduled until May 1.
- Recent recognition by TIME as a top impactful company has failed to provide a buffer against the prevailing market sell-off.